Camurus AB (CAMX) AI Stock Analysis

Compare

0 Followers

SE:CAMX Dividends

Top Page

Camurus AB

(OTC:CAMX)

68Neutral

Camurus AB demonstrates strong financial health with robust revenue growth and stable financials. However, technical indicators suggest potential resistance, and the high P/E ratio indicates valuation concerns. The company's strong financial foundation supports its position, but current market conditions may present challenges.

Camurus AB (CAMX) vs. S&P 500 (SPY)

Market Cap

kr34.68B

Dividend YieldN/A

Average Volume (3M)62.27K

Price to Earnings (P/E)80.2

Beta (1Y)0.70

Revenue Growth8.78%

EPS Growth-5.57%

CountrySE

Employees256

SectorHealthcare

Sector Strength69

IndustryBiotechnology

Share Statistics

EPS (TTM)7.35

Shares Outstanding58,879,017

10 Day Avg. Volume46,459

30 Day Avg. Volume62,269

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

Price to Cash Flow (P/CF)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

Camurus AB Business Overview & Revenue Model

Company DescriptionCamurus AB is a Swedish pharmaceutical company focused on developing and commercializing innovative specialty medicines for the treatment of chronic and severe conditions. Operating primarily in the healthcare sector, the company leverages its proprietary FluidCrystal technology to develop a range of products aimed at improving patient quality of life. Camurus is particularly active in the areas of pain management, oncology, and the treatment of addiction.

How the Company Makes MoneyCamurus AB generates revenue through the sales and licensing of its pharmaceutical products. The company's proprietary FluidCrystal technology serves as a platform for developing long-acting injectable treatments, which are licensed to other pharmaceutical companies, thereby generating licensing fees and royalties. Additionally, Camurus markets its own products, such as Buvidal, which is used for the treatment of opioid dependence, directly contributing to its revenue. Significant partnerships with healthcare providers and pharmaceutical companies also play a crucial role in extending the reach of its products, further supporting its financial performance.

Camurus AB Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Breakdown
Income Statement		Total Revenue
1.87B	1.72B	956.34M	600.57M	336.00M
	Gross Profit
1.74B	1.59B	853.08M	515.22M	300.71M
	EBIT
469.17M	532.36M	71.96M	-112.36M	-206.57M
	EBITDA
568.24M	562.54M	87.59M	-97.72M	-196.58M
	Net Income Common Stockholders
428.39M	431.44M	55.55M	-90.45M	-167.26M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
2.85B	1.19B	565.54M	411.57M	461.79M
	Total Assets
3.76B	1.91B	1.31B	1.08B	1.04B
	Total Debt
17.04M	24.51M	26.22M	25.66M	25.48M
	Net Debt
-2.84B	-1.17B	-539.32M	-385.92M	-436.31M
	Total Liabilities
467.33M	414.82M	310.82M	232.99M	196.66M
	Stockholders Equity
3.29B	1.49B	994.67M	848.91M	847.44M
Cash Flow		Free Cash Flow
358.62M	596.75M	99.29M	-148.37M	-242.16M
	Operating Cash Flow
387.99M	606.88M	101.20M	-143.43M	-238.83M
	Investing Cash Flow
-29.37M	-10.13M	5.38M	-4.94M	-3.33M
	Financing Cash Flow
1.30B	28.76M	43.70M	98.90M	347.85M

Camurus AB Technical Analysis

Technical Analysis Sentiment

Neutral

Last Price566.00

Price Trends

50DMA

598.79

Negative

100DMA

587.66

Positive

200DMA

615.04

Negative

Market Momentum

MACD

-4.28

Negative

RSI

54.52

Neutral

STOCH

92.49

Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CAMX, the sentiment is Neutral. The current price of 566 is above the 20-day moving average (MA) of 561.77, below the 50-day MA of 598.79, and below the 200-day MA of 615.04, indicating a neutral trend. The MACD of -4.28 indicates Negative momentum. The RSI at 54.52 is Neutral, neither overbought nor oversold. The STOCH value of 92.49 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:CAMX.

Camurus AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CAMX	68 Neutral	kr34.68B	80.15	18.16%	―	8.78%	-5.57%
Sector *	51 Neutral	$5.32B	3.41	-40.36%	2.89%	17.93%	2.52%
XBRANE	47 Neutral	kr296.79M	―	-138.15%	―	-16.76%	73.00%
BIOA.B	43 Neutral	kr16.75B	―	-18.00%	―	-58.22%	-177.07%
SYNACT	40 Neutral	€978.22M	―	-43.97%	―	―	67.70%
HNSA	39 Underperform	kr1.46B	―		―	9.53%	41.19%
XSPRAY	34 Underperform	kr1.08B	―	-42.78%	―	―	-19.44%

* Healthcare Sector Average

Performance Comparison

SE:CAMX

Camurus AB

589.00

92.60

18.65%

SE:HNSA

Hansa Biopharma AB

28.36

-0.64

-2.21%

SE:BIOA.B

BioArctic AB Class B

189.20

-9.80

-4.92%

SE:XBRANE

Xbrane Biopharma AB

0.19

-0.01

-7.21%

SE:XSPRAY

Xspray Pharma AB

35.00

-4.82

-12.11%

SE:SYNACT

SynAct Pharma AB

19.96

13.12

191.73%

Camurus AB Earnings Call Summary

Earnings Call Date: Feb 13, 2025 | % Change Since: -3.50% | Next Earnings Date: May 15, 2025

Earnings Call Sentiment Positive

The earnings call presented strong financial performance and growth in key product sales, along with a solid cash position. However, challenges such as the FDA's CRL and increased operating expenses were noted. The positive aspects of growth and profitability were more pronounced, leading to an optimistic outlook.

Highlights

Record Revenue Growth

Camurus achieved a revenue growth of 38% year-on-year, reaching SEK 480 million, excluding a one-time revenue in 2023.

Increased Profitability

Profit before tax increased by 125% to SEK 165 million in Q3, excluding the one-time milestone.

Strong Cash Position

Cash position increased to SEK 2.75 billion, with no debt.

Buvidal and Brixadi Sales Growth

Buvidal sales grew by 22% year-on-year to SEK 421 million, and Brixadi net sales increased by 39% quarter-on-quarter, resulting in a SEK 58 million royalty contribution.

Positive R&D Advancements

Advanced R&D pipeline with positive Phase III results from the ACROINNOVA 2 study and progress in U.S. NDA labeling.

Lowlights

FDA Complete Response Letter

Received a CRL from the FDA due to cGMP inspection at a third-party manufacturer, pending classification.

Slight Market Slowdown

The third quarter showed a slight slowdown in market growth, attributed to seasonal factors.

Increased Operating Expenses

Total OpEx reached SEK 304 million, a 21% increase versus the prior year, driven by marketing and distribution investments.

Company Guidance

During the Q3 2024 earnings call for Camurus (CAMX.ST), the company provided an optimistic update on its financial and operational performance. Revenue in the third quarter increased by 38% year-on-year to SEK 480 million, with an impressive profit before tax surge of 125% to SEK 165 million. The quarter also saw Buvidal sales climb by 22% to SEK 421 million, while Brixadi net sales in the U.S. rose by 39% quarter-on-quarter, contributing SEK 58 million in royalties. The company's gross margin reached 93%, and its cash position improved to SEK 2.75 billion, maintaining a debt-free status. The company revised its full-year 2024 outlook upwards, anticipating total revenue between SEK 1,810 million and SEK 1,880 million, and a profit before taxes in the range of SEK 450 million to SEK 510 million. R&D advancements were highlighted by positive Phase III results and ongoing regulatory progress, despite a CRL from the FDA due to a cGMP inspection issue. Camurus remains focused on meeting its 2027 vision, buoyed by strong year-to-date performance and promising Q4 expectations.

Glossary

OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.

NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.

UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.